Patents by Inventor Suzette Carr

Suzette Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule
    Patent number: 8497247
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as diabetes, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: July 30, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHOD FOR TREATING A RHEUMATIC DISEASE USING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20120258094
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as diabetes, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: February 24, 2012
    Publication date: October 11, 2012
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
    Patent number: 8227420
    Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: July 24, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Method for treating a rheumatic disease using a soluble TLA4 molecule
    Patent number: 8148332
    Abstract: The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHOD FOR TREATING A RHEUMATIC DISEASE USING A SOLUBLE TLA4 MOLECULE
    Publication number: 20110311529
    Abstract: The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: July 27, 2011
    Publication date: December 22, 2011
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHOD FOR TREATING AN AUTOIMMUNE DISEASE USING A SOLUBLE CTLA4 MOLECULE AND A DMARD OR NSAID
    Publication number: 20100166756
    Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).
    Type: Application
    Filed: March 9, 2010
    Publication date: July 1, 2010
    Inventors: ROBERT COHEN, SUZETTE CARR, DAVID HAGERTY, ROBERT JAMES PEACH, JEAN-CLAUDE BECKER
  • Methods for treating immune system diseases using a soluble CTLA4 molecule
    Patent number: 7455835
    Abstract: The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: November 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Robert James Peach, David Hagerty, Suzette Carr, Jean-Claude Becker, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
    Publication number: 20040022787
    Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).
    Type: Application
    Filed: April 18, 2003
    Publication date: February 5, 2004
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert J. Peach, Jean-Claude Becker
  • Methods for treating rheumatic diseases using a soluble CTLA4 molecule
    Publication number: 20030083246
    Abstract: The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: July 2, 2001
    Publication date: May 1, 2003
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert J. Peach, Jean-Claude Becker